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Abstract
Background: Ultrasonography (US) is widely used as a standard surveillance tool for patients who are at a high risk
of having hepatocellular carcinoma (HCC); however, conventional B-mode US appears to be insufficient in order to
ensure the early detection of HCC. Perfluorobutane allows very stable Kupffer phase imaging for at least 60 min,
which is tolerable for examinations of the entire liver. The purpose of our study is to evaluate the added value of
contrast-enhanced US using perfluorobutane to that of conventional B-mode US as an HCC surveillance tool for
patients with liver cirrhosis.
Methods/Design: SCAN (Sonazoid-US for surveillance of hepatoCellulArcarciNoma) is a prospective, multi-institutional,
diagnostic trial using an intra-individual comparison design in a single arm of patients. This study was approved by our
five institutional review board and informed consent was obtained from all participating. We obtained consent for
publication of these data (contrast enhanced US images, CT or MRI images, laboratory findings, age, sex) from all
participating patients. All patients will undergo conventional B-mode US immediately followed by contrast-enhanced
US. The standardized case report forms will be completed by operating radiologists after B-mode US and contrast-
enhanced US, respectively. If any lesion(s) is detected, the likelihood of HCC will be recorded. The primary endpoints
are a detection rate of early-stage HCC and a false referral rate of HCC. Intra-individual comparison using Mcnemar’s
test will be performed between B-mode US and contrast-enhanced US. The study will include 523 patients under HCC
surveillance in five medical institutions in Korea.
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Discussion: SCAN is the first study to investigate the efficacy of contrast-enhanced US in surveillance using two
reciprocal endpoints specialized for the evaluation of a surveillance test. SCAN will provide evidence regarding whether
patients can truly benefit from contrast-enhanced US in terms of the detection of early stage HCC while avoiding
additional unnecessary examinations. In addition to the study protocol, we elaborate on potentially debatable
components of SCAN, including the design of an intra-individual comparison study, study endpoints, composite
reference standards, and indefinite imaging criteria regarding the likelihood of HCC.
Trial registration: The date of trial registration (ClincalTrials.gov: NCT02188901) in this study is July 3, 2014. The last
patient enrolled in August 30, 2016 and follow up to see the primary end point is still ongoing. All authors have no
other relationships/conditions/circumstances that present a potential conflict of interest of relationships. Our study
protocol has undergone peer-review by the funding body (GE Healthcare). No other relationships/conditions/
circumstances that present a potential conflict of interest. Also, we clearly stated in the 'competing interests' section of
my manuscript.
Background
Currently, clinical practice guidelines recommend semi-
annual surveillance for patients who are at a high risk
of having hepatocellular carcinoma (HCC) [1–4]. While
ultrasonography (US) has been used as a standard
examination for HCC surveillance [5], the reported
sensitivities, varying from 59% to 92% [6], appear to be
insufficient to ensure the early detection of HCC. Using
US contrast agents, attempts have been made to im-
prove the efficacy of US in diagnosing HCC; however,
US contrast agents in surveillance settings have only
rarely been validated [6].
Perfluorobutane (Sonazoid; GE Healthcare, Oslo,
Norway) is a second-generation US contrast agent, which
has unique characteristics allowing Kupffer phase imaging.
Kupffer cells, liver-specific macrophages, phagocytize the
perfluorobutane [7] and amplify the ultrasound scattering
in order to generate the amplified sound wave. Therefore,
a hepatic lesion in which the number of Kupffer cells are
either markedly decreased or absent shows a defect on US
during the Kupffer phase. Perfluorobutane has been stud-
ied for various applications such as the diagnosis of focal
liver lesions [8–13], grading of the histologic differenti-
ation of HCCs [14, 15], and guidance of surgical or radio-
logical interventions [16–19].
As the Kupffer phase lasts at least 60 minutes with
high stability and allows sufficient time to examine
the entire liver, we have noted the value of perfluoro-
butane as a surveillance tool. One earlier, brief report
showed that there was improvement in the detection
of small HCCs using perfluorobutane [9]. However, it
is still unclear whether patients truly benefit from
contrast-enhanced US in terms of the detection of
early-stage HCC while avoiding unnecessary add-
itional examinations. The purpose of this study is to
investigate the added value of contrast-enhanced US
to conventional B-mode US as an HCC surveillance
tool in patients with liver cirrhosis.
Method/design
Design
Sonazoid-US for surveillance of hepatoCellulArcarci-
Noma (SCAN) is a prospective, multi-institution, diag-
nostic trial using an intra-individual comparison design
in a single-arm of patients. The primary endpoints are a
detection rate of early-stage HCC and a false referral
rate. Our study will include 523patientsunder HCC sur-
veillance at five medical institutions (Seoul National
University Bundang Hospital, Seoul National University
College of Medicine, Severance Hospital, Yonsei Univer-
sity College of Medicine, University of Ulsan College of
Medicine, Asan Medical Center, Samsung Medical Cen-
ter, Sungkyunkwan University School of Medicine, Seoul
National University Hospital) in Korea. The institutions
were chosen based on their potential to recruit a high
number of patients currently in HCC surveillance. The
SCAN protocol and the informed consent form have
been approved by the ethics committee of each partici-
pating institution. Recruitment commenced in October
2014. The date of trial registration (ClincalTrials.gov:
NCT02188901) in this study is July 3, 2014. The last pa-
tient enrolled in August 30, 2016 and follow up to see
the primary end point is still ongoing. All authors have
no other relationships/conditions/circumstances that
present a potential conflict of interest of relationships.
Eligibility criteria
Patients aged 20 to 80 years, having liver cirrhosis related
to HBV, HCV or primary biliary cirrhosis, and undergoing
US for HCC surveillance are eligible for the study. Liver cir-
rhosis is defined as having one of following criteria [20]: (a)
histologically proven liver cirrhosis (METAVIR score 4); (b)
endoscopically or radiologically identified esophageal or
gastric varices; (c) hepatic surface nodularity seen on a pre-
vious cross-sectional imaging study such as US, computed
tomography or magnetic resonance imaging; (d)serum
platelet count <100,000 /mm3; (e) serum albumin <3.5 g/
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dL; and (f) prothrombin time–international normalized ra-
tio (PT-INR)>1.3. Patients are not eligible for the study if
they have history of HCC (either treated or not treated) or
a contraindication for the perfluorobutane.
US technique
All patients will undergo contrast-enhanced US
(Kupffer-phase US ± vascular-phase US) immediately
following conventional B-mode US lying in the supine and/
or left lateral decubitus position. One of the fellowship-
trained abdominal radiologists in each participating institu-
tion, and who is aware of the patient’s previous clinical and
radiological information, performs B-mode US using an
ultrasound system (LOGIQ E9, GE Healthcare, Milwaukee,
WI, USA) equipped with a convex transducer operating at
a frequency of 1 to 6 megahertz. 16 μg of perfluorobutane
is dissolved in 2 mL of sterile water, and the solution is
intravenously administrated as a bolus at a dose of 0.015
mL/kg body weight, immediately followed by a 10-mL nor-
mal saline flush via the antecubital vein. Ten to 15 minutes
after the perfluorobutane administration, the same radiolo-
gist performs contrast-enhanced US during the Kupffer-
phase with the same ultrasound system. If a new lesion is
detected on the preceding B-mode US, vascular-phase US
will be performed for the target lesion before the Kupffer-
phase and during the arterial (10-40 seconds after adminis-
tration of perfluorobutane), portal venous (60-90 seconds),
and delay (3 minutes)phases. If a new lesion is detected
only o n Kupffer-phase US, vascular-phase US will be
performed for detecting the target lesion after the Kupffer-
phase with re-administration of the same dose of perfluoro-
butane [9] (Fig. 1). All phases are to be recorded as movie
clips. Some representative images, especially in the arterial
and Kupffer- phases, are obtained and sent to a picture ar-
chiving and communications system (PACS).If there are
two or more lesions in a single patient, vascular-phase US
will be performed for the largest lesion. In performing US,
the radiologists follow the guidelines of the Korean Society
of Ultrasound in Medicine [21]. Otherwise, there are no
specific restrictions regarding the US technique or time
constraint. The scanning parameters are detailed in Table 1.
Image interpretation
The standardized case report forms will be completed by
the operating radiologist after completion of B-mode US
and contrast-enhanced US respectively, and will include
the subjective quality of the US examination (acceptable
or incomplete), the presence or absence of a lesion, and
the presence of portal-venous thrombosis. If any le-
sion(s) is detected, the number, size, location according
to Couinaud’s classification, sonographic features, en-
hancement pattern, and the likelihood of HCC (using a
3-point Likert scale: benign, probably benign, and suspi-
cious HCC) of the lesion(s) are also to be recorded. The
imaging criteria for the likelihood of HCC are not proto-
colled, and the judgement for the likelihood of HCC will
be left to the discretion of the radiologists.
Further imaging work-up
If a patient has any lesion(s) of which the likelihood of
HCC is grade 3 (suspicious HCC) on either B-mode US
or contrast-enhanced US, the patient will undergo CT
or MRI for further characterization of the lesion(s)
within 60 days after the surveillance US. For patients in
Fig. 1 Study flow diagram*After re-administration of perfluorobutane.CT computed tomography, HCC hepatocellular carcinoma, MRI magnetic
resonance imaging, US ultrasonography
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whom no lesion is identified or in those with a lesion in
which there is a likelihood of HCC ≤ grade 2 on both B-
mode US and contrast-enhanced US, follow-up imaging
will be recommended according to the standard surveil-
lance program of each participating institution.
Reference standards
For patients undergoing hepatic surgery or biopsy, the
final diagnosis will be determined based on the patho-
logical HCC criteria as follows [22]. (a) The hepatocellu-
lar origin of the tumor verified by architectural and
cytological evidence of hepatocellular differentiation. (b)
The presence of malignant features such as nuclear aty-
pia and architectural alteration. Three immunohisto-
chemical markers including glypican 3, heat shock
protein 70, and glutamine synthetase are used for differ-
entiating between the high-grade dysplastic nodule and
well-differentiated HCC. If tumor cells are positive for
two or three markers, the tumor will be diagnosed as
well-differentiated HCC. For patients who do not
undergo surgery or biopsy, the radiology expert panel in
the central review unit will determine the final diagnosis
using CT or MRI based on the Liver Imaging Reporting
and Data System (LI-RADS) version 2014 [23, 24]. Image
findings compatible with LR-4, LR-5 and LR5V will be di-
agnosed as HCC. The expert panel consists of radiologists
who are not involved in the prospective US examination.
They will be aware of the study concept and design, al-
though they will be blinded to the details of the US results.
As all analyses in SCAN will be performed in a per-
patient manner, there will be no additional process which
determines if a lesion identified on CT or MRI matches
the lesion identified on the surveillance US.
Primary endpoints
The primary study endpoints are a detection rate of
early-stage HCC and a false referral rate. The detection
rate of early-stage HCC is defined as the proportion of
patients having both positive US results and confirmed
as having early-stage HCCs on reference standard proce-
dures out of all patients enrolled in the study. The early-
stage HCC is defined as a single HCC<5cm or up to
three HCCs, each of which is less than 3 cm based on
the Barcelona Clinic Liver Cancer staging system (BCLC
stage 0 or A) [25]. The false referral rate is defined as
the proportion of patients having positive US results but
confirmed as not having HCC on reference standard
procedures out of all patients enrolled in the study.
The likelihood of HCC = grade 3 will be regarded as
test positive both for B-mode US and contrast-enhanced
US. If a patient has two or more lesions, the lesion
assigned the greatest likelihood of HCC will be regarded
as the representative lesion of that patient. As patients
who have positive results either on B-mode US or on
contrast-enhanced US subsequently undergo reference
standard procedures, the true-positives and false refer-
rals are to be determined by comparing the case report
forms of each US method with the reference standards.
For example, if a patient has a lesion of which the likeli-
hood of HCC is grade 3 on B-mode US but is grade 2
on contrast-enhanced US, and if the patient is finally
confirmed as not having HCC on reference standard
procedures, it will be counted as a false referral of B-
mode US but not of contrast-enhanced US.
Secondary endpoints
The secondary endpoints include a detection rate of
HCC of any stage adverse event rate of perfluorobutane.
The detection rate of HCC of any stage is defined as the
proportion of patients having both positive US results
and confirmed HCCs of any stage out of the patients en-
rolled in the study. The adverse event rate is defined as
the proportion of patients having an adverse event fol-
lowing injection of perfluorobutane out of the patients
enrolled in the study. Short-term and long-term adverse
events are to be recorded according to the Common
Terminology Criteria for Adverse Events (CTCAE ver-
sion 4.0) [26] with structured telephone interviews three
and 90 days after the surveillance US.
Stopping rule
If one or more life-threatening or fatal serious adverse
events (SAEs) are reported in any of study patients,
Table 1 Contrast-enhanced US performed according to
theperfluorobutane(Sonazoid) protocol
Imaging protocol
Intravenous access Antecubital or forearm
Contrast preparation 16 μg of perfluorobutane dissolved in
2 mL of sterile water
Injection dose 0.015 mL/kg body weight
Injection method Bolus with 10-mL normal saline flush
Contrast US setting
Scanning view Dual view ( B-mode + contrast mode)
Mechanical index 0.20 -0.26
Dynamic range 60 - 65dB
Location of the beam
focus




Kupffer phase 10 to 15 minutes after the injection of
perfluorobutane
Vascular phase After reinjection of perfluorobutane
Artery phase 10-40 seconds
Portal phase 60-90 seconds
Delay phase 3–4 minutes
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SCAN will be suspended and the study coordinating
committee will investigate if the events are attributable
to study procedures and determine whether or not
SCAN should be terminated early.
Sample size
For sample size calculation, we assumed a 5% prevalence
of HCC in our target population, a 3.15% detection rate
of early-stage HCC on B-mode US (63% of sensitivi-
ty)[27],and a4.75% detection rate of early-stage HCC on
contrast-enhanced US (95% of sensitivity) [8]. We also
assumed a 1.7% discordant rate which included0.05% of
the proportion of patients in whom a lesion is detected
on B-mode US but not on contrast-enhanced US. With
these assumptions, 523patients are needed to obtain
80% statistical power for the McNemar’s test with an α
equal to 0.05.
Data management
Trained research associates will perform data checks for
accuracy and completeness. Using an electronic case re-
port form, the data will be entered into the database.
The collected data will be kept in the central data arch-
ive of the data center, which has a built-in security fea-
ture preventing unauthorized access to confidential
participant information.
Data analysis
While intention-to-treat analysis will be primarily per-
formed for all patients enrolled in the study, per-protocol
analysis will also be performed for patients who follow the
study protocol without violation. Intra-individual com-
parison will be made between B-mode US and contrast-
enhanced US in terms of the detection rate of early-stage
HCC, the false referral rate, and the detection rate of any
stage HCC using McNemar’s test in a per-patient manner.
Subgroup analyses will be performed for each end-
point according to a patient’s age, gender, body mass
index, cirrhosis etiology, history of anti-viral treatment,
Child-Pugh score, Albumin-Bilirubin (ALBI) grade [28],
and alpha-fetoprotein (AFP). We will use logistic regres-
sion models with a generalized linear mixed model
(GLMM) including random intercept for the patients if
the study results show considerable variation across the
participating institutions. P values less than 0.05 are con-
sidered statistically significant. All statistical analyses will
be performed using commercially available software
(SAS Ver. 9.2; SAS Institute, Cary, NC, USA).
Discussion
Study design
We designed SCAN as an intra-individual comparison
study rather than a randomized controlled trial (RCT).
Due to the lack of previous researcher grading contrast-
enhanced US in surveillance, it was impossible to set the
appropriate effect size for an RCT. The lack of baseline
data also raised a concern regarding the equipoise that
could justify the randomization. Although we could not
use the design of an RCT, intra-individual comparison
has obvious advantages as it would allow for an excellent
comparability between a pair of results and would also
increase the statistical power for a given number of
study patients. Unlike typical therapeutic or interven-
tional trials, the diagnostic examinations investigated in
diagnostic trials can be repeatedly applied to the same
patient without affecting the disease status. We expect
that the results of SCAN will offer not only the efficacy
of contrast-enhanced US but also relevant baseline data
for future studies on US surveillance.
Study endpoints
The accuracy of a diagnostic test can ideally be evaluated
with a definitive diagnosis, usually in terms of sensitivity
and specificity. However, studies investigating the effi-
cacy of US in surveillance settings have frequently been
limited by verification bias [27]. This is because the de-
finitive diagnostic procedure is used on patients who
have positive results, while those who have negative re-
sults are not confirmed as true or false negatives, which
indicates that neither sensitivity nor specificity is identi-
fiable [29]. A detection rate and a false referral rate are
two important reciprocal measures which do not require
definitive diagnoses from all study patients and allow a
comparison of the relative performance of two screening
tests [29, 30]. While we expect improvement of the de-
tection rate of early-stage HCC by adding contrast-
enhanced US to conventional B-mode US, the improve-
ment can be truly valuable only if the false referral rate
is decreased or at least remains stable.
Composite reference standards
We set composite reference standards in SCAN, which
uses either histopathology or radiology as the final diag-
nosis of HCC. Various treatments, such as surgery, ra-
diofrequency ablation, percutaneous ethanol injection,
and combined therapy of radiofrequency ablation and
trans-arterial chemoembolization, are currently available
for early-stage HCCs [1, 2, 31]. This makes the investiga-
tion of the efficacy of a diagnostic test for HCC more
complex as histopathology, which has traditionally been
used as the reference standard for imaging diagnosis, is
not available in most patients. Furthermore, the very
high specificity of the typical radiological features of
HCC in an at-risk population rendered the imaging diag-
nosis a substitute for histopathology, and the recently
updated American Association for the Study of Liver
Diseases (AASLD) guidelines have even proposed that
one imaging technique (either CT or MRI) showing the
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typical radiological features suffices for diagnosing HCC
[2]. It is now regarded as unethical to perform a biopsy
on a patient with HCC, in whom the biopsy is unneces-
sary for clinical purposes. If we use only histopathology
as the reference standard, it should result in a significant
bias as then only HCCs showing atypical radiological
features will be included as true HCCs.
Imaging criteria for the likelihood of HCC
As the imaging criteria for the likelihood of HCC are
not protocolled in SCAN, the diagnosis will be left to
the discretion of the radiologists who conduct and inter-
pret the US. In previous research studies evaluating the
efficacy of US in the surveillance setting, the criteria de-
fining which lesion should trigger further investigation
were usually absent or, if any, they differed from the
other criteria [32–43]. Considering the subjectivity of US
interpretation and the diverse sonographic features of
HCC [44], the current guidelines often suggest that any
new lesion detected on US, regardless of its echogenic
pattern, should be further evaluated by CT or MRI.
However, there is still a discrepancy between the guide-
lines regarding the use of the size criterion. While
AASLD and The European Association for the Study of
the Liver (EASL)guidelines suggest a 1-cm criterion [1,
2], guidelines from the Asian-Pacific region do not have
such a criterion in the diagnostic algorithms [3, 45, 46].
Furthermore, the clinical significance of a lesion smaller
than 1 cm and showing a defect on Kupffer-phase US
has not yet been established. Therefore, we have decided
not to list specific imaging criteria for the likelihood of
HCC which do not reflect current variations in clinical
practice.
SCAN is the first study to investigate the efficacy
of contrast-enhanced US in surveillance using two
reciprocal endpoints specialized for evaluation of a
surveillance test. SCAN will provide evidence re-
garding whether patients can truly benefit from
contrast-enhanced US in terms of the detection of
early stage HCC while avoiding additional unneces-
sary examinations.
Abbreviations
AFP: Alpha-fetoprotein; ALBI: Albumin-Bilirubin; BCLC: Barcelona Clinic Liver
Cancer staging system; CTCAE: Common Terminology Criteria for Adverse
Events; EASL: The European Association for the Study of the Liver;
GLMM: Generalized linear mixed model; HCC: Hepatocellular carcinoma; LI-
RADS: Liver Imaging Reporting and Data System; PACS: Picture archiving and
communications system; RCT: Randomized controlled trial; SAEs: Serious
adverse events; US: Ultrasonography
Funding
Our study protocol has undergone peer-review by the funding body (Health-
care Life Science Core Imaging: Award Number: SON-14-01).
Availability of data and material
The date of trial registration (ClincalTrials.gov: NCT02188901) in this study is
July 3, 2014. The last patient enrolled in August 30, 2016 and follow up to
see the primary end point is still ongoing. However, our research has not yet
published any results or submission.
Authors’ contributions
We had to include ten authors, all ten authors significantly contributed to
the study and fulfilled the ICMJE criteria for authorship. Therefore, all of them
may deserve being listed as authors. It would be much appreciated if all ten
authors are acceptable. Specific author contributions according to the ICMJE
criteria are as follows. Criteria I - Conception and design: JHP, M-SP, SJL, WKJ,
JYL, MJP, KhH, CMN, SHP, KHL - Acquisition of data: JHP, M-SP, SJL, WKJ, JYL,
- Analysis and interpretation of data: JHP, M-SP, SJL, WKJ, JYL, Criteria II -
Drafting the article: JHP, M-SP, SJL Criteria III - Final approval of the version:
all authors
Competing interests
The author(s) declare(s) that they have no competing interests.
Consent for publication
We obtained consent for publication of these data (contrast enhanced US
images, CT or MRI images, laboratory findings, age, sex) from all participating
patients.
Ethics approval and consent to participate
The study will include 523 patients under HCC surveillance in five medical
institutions (Seoul National University Bundang Hospital, Seoul National
University College of Medicine, Severance Hospital, Yonsei University College of
Medicine, Asan Medical Center, Samsung Medical Center) in Korea. This study
was approved by our five institutional review board (Severance Hospital e-IRB:
http://eirb.yuhs.ac/, Seoul National Hospital e-IRB: https://cris.snuh.org/ncris/,
Seoul National Bundang Hospital e-IRB: https://e-irb.snubh.org/, Asan Medical
Center e-IRB: http://eirb.amc.seoul.kr/, Samsung Medical Center e-IRB: http://
www.e-irb.com/index.jsp) and informed consent was obtained from all
participating.




Seoul National Hospital Seoul National Bundang
Hospital











Jae yen, Park Jung hee, Cha Jeen Hee, Han Gi Hye, Yang Hae min, Suk
E-mail Iampark90@yuh.ac snuhirb@gmail.com 02100@snubh.org jhyang@amc.seoul.kr Hm.seok@samsung.com
Tel. 82-2-2228-0430 82-2-2072-0694 82-31-787-1377 82-2-3010-7162 82-2-3410-3671
IRB No. 4-2014-0337 H-1405-133-583 B-1407/259-001 2014-0768 NCT02188901
Park et al. BMC Cancer  (2017) 17:279 Page 6 of 8
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Radiology, Seoul National University Bundang Hospital, Seoul
National University College of Medicine, Institute of Radiation Medicine,
Seoul National University Medical Research Center, Gyeonggi-do, Republic of
Korea. 2Department of Radiology and Research Institute of Radiological
Science, Severance Hospital, Yonsei University College of Medicine, Seoul,
Republic of Korea. 3Department of Radiology and Research Institute of
Radiology, University of Ulsan College of Medicine, Asan Medical Center,
Seoul, Republic of Korea. 4Department of Radiology and Center for Imaging
Science, Samsung Medical Center, Sungkyunkwan University School of
Medicine, Seoul, Republic of Korea. 5Department of Radiology and Institute
of Radiation Medicine, Seoul National University Hospital, Seoul, Republic of
Korea. 6Department of Radiology, Ajou University Hospital, Ajou University
School of Medicine, Suwon, Republic of Korea. 7Yonsei Biomedical Research
Institute, Department of Radiology, Research Institute of Radiological Science
Yonsei University College of Medicine, Seoul, Republic of Korea. 8Department
of Biostatistics, Yonsei University College of Medicine, Seoul, Republic of
Korea.
Received: 5 January 2017 Accepted: 5 April 2017
References
1. European Association For The Study Of The Liver, European
Organisation For Research And Treatment Of Cancer. EASL-EORTC
clinical practice guidelines: management of hepatocellular carcinoma. J
Hepatol. 2012;56(4):908–43.
2. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update.
Hepatology. 2011;53(3):1020–2.
3. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, et al. Asian
Pacific Association for the Study of the Liver consensus recommendations
on hepatocellular carcinoma. Hepatol Int. 2010;4(2):439–74.
4. Santi V, Trevisani F, Gramenzi A, Grignaschi A, Mirici-Cappa F, Del Poggio P,
et al. Semiannual surveillance is superior to annual surveillance for the
detection of early hepatocellular carcinoma and patient survival. J Hepatol.
2010;53(2):291–7.
5. Pocha C, Dieperink E, McMaken KA, Knott A, Thuras P, Ho SB. Surveillance
for hepatocellular cancer with ultrasonography vs. computed tomography –
a randomised study. Aliment Pharmacol Ther. 2013;38(3):303–12.
6. Chou R, Cuevas C, Fu R, Devine B, Wasson N, Ginsburg A, et al. Imaging
Techniques for the Diagnosis of Hepatocellular Carcinoma: A Systematic
Review and Meta-analysis. Ann Intern Med. 2015;162(10):697–711.
7. Yanagisawa K, Moriyasu F, Miyahara T, Yuki M, Iijima H. Phagocytosis of
ultrasound contrast agent microbubbles by Kupffer cells. Ultrasound Med
Biol. 2007;33(2):318–25.
8. Kan M, Hiraoka A, Uehara T, Hidaka S, Ichiryu M, Nakahara H, et al.
Evaluation of contrast-enhanced ultrasonography using perfluorobutane
(Sonazoid((R))) in patients with small hepatocellular carcinoma: comparison
with dynamic computed tomography. Oncol Lett. 2010;1(3):485–8.
9. Kudo M, Hatanaka K, Kumada T, Toyoda H, Tada T. Double-contrast
ultrasound: a novel surveillance tool for hepatocellular carcinoma. Am J
Gastroenterol. 2011;106(2):368–70.
10. Goto E, Masuzaki R, Tateishi R, Kondo Y, Imamura J, Goto T, et al. Value of
post-vascular phase (Kupffer imaging) by contrast-enhanced
ultrasonography using Sonazoid in the detection of hepatocellular
carcinoma. J Gastroenterol. 2012;47(4):477–85.
11. Kunishi Y, Numata K, Morimoto M, Okada M, Kaneko T, Maeda S, et al.
Efficacy of fusion imaging combining sonography and hepatobiliary phase
MRI with Gd-EOB-DTPA to detect small hepatocellular carcinoma. AJR Am J
Roentgenol. 2012;198(1):106–14.
12. Sugimoto K, Moriyasu F, Shiraishi J, Saito K, Taira J, Saguchi T, et al.
Assessment of arterial hypervascularity of hepatocellular carcinoma:
comparison of contrast-enhanced US and gadoxetate disodium-enhanced
MR imaging. Eur Radiol. 2012;22(6):1205–13.
13. Alaboudy A, Inoue T, Hatanaka K, Chung H, Hyodo T, Kumano S, et al.
Usefulness of combination of imaging modalities in the diagnosis of
hepatocellular carcinoma using Sonazoid(R)-enhanced ultrasound,
gadolinium diethylene-triamine-pentaacetic acid-enhanced magnetic
resonance imaging, and contrast-enhanced computed tomography.
Oncology. 2011;81(Suppl 1):66–72.
14. Arita J, Takahashi M, Hata S, Shindoh J, Beck Y, Sugawara Y, et al. Usefulness
of contrast-enhanced intraoperative ultrasound using Sonazoid in patients
with hepatocellular carcinoma. Ann Surg. 2011;254(6):992–9.
15. Maruyama H, Takahashi M, Sekimoto T, Kamesaki H, Shimada T, Kanai F, et
al. Heterogeneity of microbubble accumulation: a novel approach to
discriminate between well-differentiated hepatocellular carcinomas and
regenerative nodules. Ultrasound Med Biol. 2012;38(3):383–8.
16. Mitsunori Y, Tanaka S, Nakamura N, Ban D, Irie T, Noguchi N, et al. Contrast-
enhanced intraoperative ultrasound for hepatocellular carcinoma: high
sensitivity of diagnosis and therapeutic impact. J Hepatobiliary Pancreat Sci.
2013;20(2):234–42.
17. Zhang XY, Luo Y, Wen TF, Jiang L, Li C, Zhong XF, et al. Contrast-enhanced
ultrasound: Improving the preoperative staging of hepatocellular carcinoma
and guiding individual treatment. World J Gastroenterol. 2014;20(35):12628–36.
18. Hiraoka A, Hiasa Y, Onji M, Michitaka K. New contrast enhanced
ultrasonography agent: impact of Sonazoid on radiofrequency ablation. J
Gastroenterol Hepatol. 2011;26(4):616–8.
19. Masuzaki R, Shiina S, Tateishi R, Yoshida H, Goto E, Sugioka Y, et al.
Utility of contrast-enhanced ultrasonography with Sonazoid in
radiofrequency ablation for hepatocellular carcinoma. J Gastroenterol
Hepatol. 2011;26(4):759–64.
20. Suk KT, Baik SK, Yoon JH, Cheong JY, Paik YH, Lee CH, et al. Revision and
update on clinical practice guideline for liver cirrhosis. Korean J Hepatol.
2012;18(1):1–21.
21. The Korean Society of Radiology, Korean Society of Ultrasound in Medicine:
Practice guidelines for the performance of ultrasound examinations. 2014.
http://www.ultrasound.or.kr. Accessed 2 Dec 2015.
22. Bedossa P, Paradis V. Hepatocellular Carcinoma. In: Romil S, editor.
Practical hepatic pathology: a diagnostic approach. Philadelphia:
Saunders; 2011. p. 492–6.
23. American College of Radiology: Liver imaging reporting and data system
version 2014. 2014. http://www.acr.org/Quality-Safety/Resources/LIRADS.
Accessed 2 Dec 2015.
24. Darnell A, Forner A, Rimola J, Reig M, Garcia-Criado A, Ayuso C, et al. Liver
Imaging Reporting and Data System with MR Imaging: Evaluation in
Nodules 20 mm or Smaller Detected in Cirrhosis at Screening US. Radiology.
2015;275(3):698–707.
25. Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and
treatment of hepatocellular carcinoma. Liver Transpl. 2004;10(2 Suppl 1):S115–20.
26. Common Terminology Criteria for Adverse Events v4.0. National Cancer
Institute. 2009. http://evs.nci.nih.gov/ftp1/CTCAE. Accessed 2 Dec 2015.
27. Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA, et al. Meta-analysis:
surveillance with ultrasound for early-stage hepatocellular carcinoma in
patients with cirrhosis. Aliment Pharmacol Ther. 2009;30(1):37–47.
28. Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL,
et al. Assessment of liver function in patients with hepatocellular
carcinoma: a new evidence-based approach-the ALBI grade. J Clin
Oncol. 2015;33(6):550–8.
29. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, et al.
Phases of biomarker development for early detection of cancer. J Natl
Cancer Inst. 2001;93(14):1054–61.
30. Pepe MS, Alonzo TA. Comparing disease screening tests when true disease
status is ascertained only for screen positives. Biostatistics. 2001;2(3):249–60.
31. Korean Liver Cancer Study Group (KLCSG), National Cancer Center, Korea
(NCC). 2014 KLCSG-NCC Korea Practice Guideline for the Management of
Hepatocellular Carcinoma. Gut Liver. 2015;9(3):267–317.
32. Kobayashi K, Sugimoto T, Makino H, Kumagai M, Unoura M, Tanaka N, et al.
Screening methods for early detection of hepatocellular carcinoma.
Hepatology. 1985;5(6):1100–5.
33. Oka H, Kurioka N, Kim K, Kanno T, Kuroki T, Mizoguchi Y, et al. Prospective
study of early detection of hepatocellular carcinoma in patients with
cirrhosis. Hepatology. 1990;12(4 Pt 1):680–7.
34. Pateron D, Ganne N, Trinchet JC, Aurousseau MH, Mal F, Meicler C, et al.
Prospective study of screening for hepatocellular carcinoma in Caucasian
patients with cirrhosis. J Hepatol. 1994;20(1):65–71.
35. Chalasani N, Horlander Sr JC, Said A, Hoen H, Kopecky KK, Stockberger Jr
SM, et al. Screening for hepatocellular carcinoma in patients with advanced
cirrhosis. Am J Gastroenterol. 1999;94(10):2988–93.
Park et al. BMC Cancer  (2017) 17:279 Page 7 of 8
36. Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, et al. Surveillance
programme of cirrhotic patients for early diagnosis and treatment of
hepatocellular carcinoma: a cost effectiveness analysis. Gut. 2001;48(2):251–9.
37. Caturelli E, Bartolucci F, Biasini E, Vigliotti ML, Andriulli A, Siena DA, et al.
Diagnosis of liver nodules observed in chronic liver disease patients during
ultrasound screening for early detection of hepatocellular carcinoma. Am J
Gastroenterol. 2002;97(2):397–405.
38. Santagostino E, Colombo M, Rivi M, Rumi MG, Rocino A, Linari S, et al. A 6-
month versus a 12-month surveillance for hepatocellular carcinoma in 559
hemophiliacs infected with the hepatitis C virus. Blood. 2003;102(1):78–82.
39. Mok TS, Yu SC, Lee C, Sung J, Leung N, Lai P, et al. False-negative rate of
abdominal sonography for detecting hepatocellular carcinoma in patients
with hepatitis B and elevated serum alpha-fetoprotein levels. AJR Am J
Roentgenol. 2004;183(2):453–8.
40. Sangiovanni A, Del Ninno E, Fasani P, De Fazio C, Ronchi G, Romeo R, et al.
Increased survival of cirrhotic patients with a hepatocellular carcinoma
detected during surveillance. Gastroenterology. 2004;126(4):1005–14.
41. Van Thiel DH, Yong S, Li SD, Kennedy M, Brems J. The development of de
novo hepatocellular carcinoma in patients on a liver transplant list:
frequency, size, and assessment of current screening methods. Liver Transpl.
2004;10(5):631–7.
42. Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, et al. The
natural history of compensated cirrhosis due to hepatitis C virus: A 17-year
cohort study of 214 patients. Hepatology. 2006;43(6):1303–10.
43. Paul SB, Gulati MS, Sreenivas V, Madan K, Gupta AK, Mukhopadhyay S, et al.
Evaluating patients with cirrhosis for hepatocellular carcinoma: value of
clinical symptomatology, imaging and alpha-fetoprotein. Oncology. 2007;
72(Suppl 1):117–23.
44. Catalano O, Lobianco R, Cusati B, Siani A. Hepatocellular carcinoma:
spectrum of contrast-enhanced gray-scale harmonic sonography findings.
Abdom Imaging. 2004;29(3):341–7.
45. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, et al.
Management of hepatocellular carcinoma in Japan: Consensus-Based
Clinical Practice Guidelines proposed by the Japan Society of Hepatology
(JSH) 2010 updated version. Dig Dis. 2011;29(3):339–64.
46. Lee JM, Park JW, Choi BI. 2014 KLCSG-NCC Korea Practice Guidelines for the
management of hepatocellular carcinoma: HCC diagnostic algorithm. Dig
Dis. 2014;32(6):764–77.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Park et al. BMC Cancer  (2017) 17:279 Page 8 of 8
